CHAPTER 6 142 ER+PR 0-10 124 (16.8) 13 (19.4) 30 (14.7) 54 (35.1) 27 (8.6) <0.001* 20-80 238 (32.2) 29 (43.3) 69 (33.8) 29 (18.8) 111 (35.4) 90-100 126 (17.1) 6 (9.0) 29 (14.2) 10 (6.5) 81 (25.8) Discordant 251 (34.0) 19 (28.4) 76 (37.3) 61 (39.6) 95 (30.3) Adjuvant treatmenta None 287 (38.8) 24 (36.4) 75 (36.9) 46 (30.1) 142 (45.7) <0.001* Radiotherapy 247 (33.4) 25 (37.9) 73 (36.0) 35 (22.9) 114 (36.7) Chemotherapy 77 (10.4) 8 (12.1) 19 (9.4) 34 (22.2) 16 (5.1) Chemoradiation 122 (16.5) 9 (13.6) 36 (17.7) 38 (24.8) 39 (12.5) Outcome Recurrence 198 (26.8) 4 (6.1) 58 (29.1) 72 (51.4) 64 (20.5) <0.001* Mortality 216 (29.2) 8 (11.9) 57 (27.9) 83 (53.9) 68 (21.7) <0.001* EC-related mortality 152 (20.6) 1 (1.5) 38 (19.4) 67 (45.3) 46 (14.9) <0.001* Data is presented in number (%), median (IQR). Abbreviations: N, number; POLEmut, polymerase epsilon mutant; MMRd, mismatch repair deficient; p53, protein 53; NSMP, No specific molecular profile; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial cancer; LVSI, lympho-vascular space invasion; N0, negative lymph nodes, N1, positive lymph nodes; Nx, no information about the lymph nodes; FIGO, International Federation of Gynecology and Obstetrics, ER, estrogen receptor; PR, progesterone receptor; EC, endometrial cancer a Missing data for 7 cases MI, 5 cases for FIGO stage, 6 for adjuvant treatment *P<0.05 Table 1. Continued
RkJQdWJsaXNoZXIy MTk4NDMw